Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $1.1 million.

  • Rocket Pharmaceuticals' Other Non-Current Liabilities fell 709.28% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 709.28%. This contributed to the annual value of $1.1 million for FY2024, which is 6113.76% down from last year.
  • Rocket Pharmaceuticals' Other Non-Current Liabilities amounted to $1.1 million in Q3 2025, which was down 709.28% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Non-Current Liabilities peaked at $2.9 million during Q4 2023, and registered a low of $37000.0 during Q3 2022.
  • For the 5-year period, Rocket Pharmaceuticals' Other Non-Current Liabilities averaged around $1.1 million, with its median value being $1.1 million (2024).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 495135.14% in 2023, then crashed by 6113.76% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $80000.0 in 2021, then skyrocketed by 3143.75% to $2.6 million in 2022, then increased by 13.14% to $2.9 million in 2023, then crashed by 61.14% to $1.1 million in 2024, then fell by 7.01% to $1.1 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.